Access the full text.
Sign up today, get DeepDyve free for 14 days.
Hepatitis C viral RNA in clotting factor concentrates and the developmentofhepatitis inrecipients
P. Mortimer, N. Luban, J. Kelleher, B. Cohen (1983)
TRANSMISSION OF SERUM PARVOVIRUS-LIKE VIRUS BY CLOTTING-FACTOR CONCENTRATESThe Lancet, 322
(1991)
Brussels: European Commission, DGIII
M. Zerbini, M. Musiani, S. Venturoli, G. Gallinella, D. Gibellini, G. Gentilomi, M. Placa (1990)
Rapid screening for B19 parvovirus DNA in clinical specimens with a digoxigenin-labeled DNA hybridization probeJournal of Clinical Microbiology, 28
Micheline Thauvin. Technician, Institut National de Transfusion Sanguine
Lefrère Lefrère, Mariotti Mariotti, Trepo Trepo (1993)
Testing for HCV‐RNA in commercial intravenous immunoglobulins (letter)Lancet, 341
(1989)
Symptomatic parvovirus B 19 infection and heat-treated factor IX concentrate (letter)
M. Burnouf-Radosevich, P. Appourchaux, J. Huart, Thierry Burnouf (1994)
Nanofiltration, a New Specific Virus Elimination Method Applied to High‐Purity Factor IX and Factor XI ConcentratesVox Sanguinis, 67
Committee for Proprietary Medical Products guidelines: ad hoc working party on biotechnology/pharmacy. Note for guidance: validation of virus removal and inactivation procedures ( I I W 15/89)
N. Frickhofen, J. Abkowitz, M. Safford, J. Berry, J. Antunez-de-Mayolo, A. Astrow, Robert Cohen, I. Halperin, L. King, D. Mintzer, B. Cohen, N. Young (1990)
Persistent B19 parvovirus infection in patients infected with human immunodeficiency virus type 1 (HIV-1): a treatable cause of anemia in AIDS.Annals of internal medicine, 113 12
J. Lefrère, M. Mariotti, M. Thauvin (1994)
B19 parvovirus DNA in solvent/detergent-treated anti-haemophilia concentratesThe Lancet, 343
M. Williams, B. Cohen, A. Beddall, K. Pasi, P. Mortimer, F. Hill (1990)
Transmission of Human Parvovirus B19 by Coagulation Factor ConcentratesVox Sanguinis, 58
(1994)
Eliminating parvovirus B 19 from blood products ( letter )
F. Mcomish, P. Yap, A. Jordan, H. Hart, B. Cohen, P. Simmonds (1993)
Detection of parvovirus B19 in donated blood: a model system for screening by polymerase chain reactionJournal of Clinical Microbiology, 31
BACKGROUND: B19 parvovirus (B19) may be transmitted iatrogenically by blood, and its prevalence in blood donations is estimated at 1 in 3,300 to 1 in 50,000. As a large number of blood donations make up the plasma pools used to produce plasma derivatives, even a virus as rare as B19 in a population of blood donors may result in the frequent contamination of plasma batches. The percentage of albumin batches containing B19 DNA has never been determined. STUDY DESIGN AND METHODS: The presence of B19 DNA was investigated by a polymerase chain reaction assay (with a primer pair in the VP1 region) in a total of 12 and 17 batches of 4‐ and 20‐percent albumin, respectively, from two different manufacturers. RESULTS: No B19 DNA was detected in the batches tested. CONCLUSION: The current fractionation process used to obtain these albumin preparations is seen to allow the efficient degradation and/or elimination of B19.
Transfusion – Wiley
Published: May 1, 1995
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.